No Break For Sanofi: Seals Another Diabetes Deal

Having just secured a deal with Hanmi Pharmaceutical for its long-acting diabetes products, Sanofi has wasted no time in boosting its diabetes franchise again, by entering into an agreement with Lexicon Pharmaceuticals for sotagliflozin.

More from Alimentary/Metabolic

More from Therapy Areas